
Ocular Therapeutix (NASDAQ:OCUL) remains on track to submit a U.S. marketing application this quarter for AXPAXLI, its experimental treatment for wet age-related macular degeneration, CEO Pravin Dugel said at the UBS Global Biopharma Conference in London.
Dugel said the planned application will rely on the Phase 3 SOL-1 trial, in which AXPAXLI demonstrated superiority to EYLEA, an anti-VEGF treatment, with a p-value below 0.0006. AXPAXLI is a tyrosine kinase inhibitor, or TKI, that the company is developing as a maintenance treatment.
More than two-thirds of SOL-1 patients did not require rescue treatment one year after a single AXPAXLI injection, Dugel said. He said the company believes the drug could provide sustained disease control after patients receive initial anti-VEGF injections.
Regulatory submission plans
Dugel said Ocular had a Type C meeting with the U.S. Food and Drug Administration in May and a pre-application meeting in the third quarter. He said the company has a path to submit based on SOL-1 alone and remains on track to file its new drug application in the fourth quarter.
According to Dugel, the FDA’s standards for a single-trial submission include a well-masked, properly powered study, a p-value below 0.001 and safety data from at least 300 patients exposed to the drug. He said the company has a special protocol assessment with the FDA for SOL-1.
The CEO did not provide a projected approval or launch date. He said the FDA typically responds about 60 days after a submission on whether it will accept an application for review. He also said Ocular expects an efficient review under its 505(b)(2) filing pathway, though he did not provide a timeline.
Asked whether changes in FDA leadership could affect the process, Dugel said he did not expect them to create a risk. He said the company’s team was familiar with the incoming ophthalmology division chief and pointed to the special protocol assessment as support for regulatory alignment.
Changes to SOL-R and SOL-X
While Ocular believes SOL-R will not be necessary for U.S. approval, Dugel said the study will likely be important to some regulators outside the United States. He also said it could provide commercially useful comparisons with high-dose EYLEA.
The company moved SOL-R’s primary endpoint to week 40 from week 56 and extended its planned unmasking to week 96. Dugel said delaying the unmasking reduces the risk of a major amendment during the anticipated U.S. review cycle and allows the company to study superiority against high-dose EYLEA.
Ocular expects to use safety data from approximately 130 SOL-R patients in its submission package. Dugel said moving the primary endpoint to week 40 was intended to protect the study from operational bias because patients would already have passed that point when the safety data were reviewed. He said a third party would submit the data to the FDA and that Ocular would remain masked until week 96.
The company also extended treatment intervals in its open-label SOL-X extension study to 48 weeks from 24 weeks. Dugel said the SOL-1 results gave Ocular confidence to examine annual dosing rather than duplicate six-month data expected from SOL-R.
Patient selection and diabetic retinal disease
Dugel attributed importance to patient selection when asked about a competing TKI’s recent Phase 3 miss in wet AMD. He argued that differences in the drugs, delivery systems and trial populations meant the competitor’s result did not indicate a class-wide problem.
In SOL-1, Ocular selected patients who responded to EYLEA and then allowed them to lose vision after treatment was stopped, Dugel said. SOL-R uses a different approach intended to select patients with stable disease before randomization.
Ocular is also enrolling patients in HELIOS-3, a study involving diabetic retinopathy and non-central-involving diabetic macular edema. Dugel said recruitment is progressing well and that the company is being selective about disease severity. He said Ocular removed a six-month treatment arm and is studying annual dosing.
Dugel said diabetic retinal disease will be a major focus for the company in 2027, when it expects to provide guidance as appropriate. He did not give a HELIOS-3 readout date or say whether results would arrive before SOL-R.
About Ocular Therapeutix (NASDAQ:OCUL)
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.
